Ginkgo Bioworks Holdings Statistics
Total Valuation
DNA has a market cap or net worth of $833.00 million. The enterprise value is $944.84 million.
| Market Cap | 833.00M |
| Enterprise Value | 944.84M |
Important Dates
The last earnings date was Thursday, November 5, 2026, after market close.
| Earnings Date | Nov 5, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
DNA has 67.34 million shares outstanding. The number of shares has increased by 11.06% in one year.
| Current Share Class | 55.38M |
| Shares Outstanding | 67.34M |
| Shares Change (YoY) | +11.06% |
| Shares Change (QoQ) | +3.01% |
| Owned by Insiders (%) | 14.73% |
| Owned by Institutions (%) | 54.42% |
| Float | 50.03M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 6.37 |
| Forward PS | 8.68 |
| PB Ratio | 2.02 |
| P/TBV Ratio | 2.36 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 7.23 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.72, with a Debt / Equity ratio of 1.01.
| Current Ratio | 4.72 |
| Quick Ratio | 4.51 |
| Debt / Equity | 1.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -58.22% and return on invested capital (ROIC) is -18.97%.
| Return on Equity (ROE) | -58.22% |
| Return on Assets (ROA) | -15.76% |
| Return on Invested Capital (ROIC) | -18.97% |
| Return on Capital Employed (ROCE) | -30.61% |
| Weighted Average Cost of Capital (WACC) | 9.34% |
| Revenue Per Employee | $269,592 |
| Profits Per Employee | -$517,592 |
| Employee Count | 485 |
| Asset Turnover | 0.12 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -866,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +38.21% in the last 52 weeks. The beta is 1.74, so DNA's price volatility has been higher than the market average.
| Beta (5Y) | 1.74 |
| 52-Week Price Change | +38.21% |
| 50-Day Moving Average | 10.00 |
| 200-Day Moving Average | 8.62 |
| Relative Strength Index (RSI) | 56.11 |
| Average Volume (20 Days) | 2,515,624 |
Short Selling Information
The latest short interest is 8.29 million, so 12.32% of the outstanding shares have been sold short.
| Short Interest | 8.29M |
| Short Previous Month | 7.17M |
| Short % of Shares Out | 12.32% |
| Short % of Float | 16.58% |
| Short Ratio (days to cover) | 2.40 |
Income Statement
In the last 12 months, DNA had revenue of $130.75 million and -$251.03 million in losses. Loss per share was -$4.14.
| Revenue | 130.75M |
| Gross Profit | 91.25M |
| Operating Income | -268.98M |
| Pretax Income | -278.14M |
| Net Income | -251.03M |
| EBITDA | -235.23M |
| EBIT | -268.98M |
| Loss Per Share | -$4.14 |
Balance Sheet
The company has $285.36 million in cash and $397.20 million in debt, with a net cash position of -$111.84 million or -$1.66 per share.
| Cash & Cash Equivalents | 285.36M |
| Total Debt | 397.20M |
| Net Cash | -111.84M |
| Net Cash Per Share | -$1.66 |
| Equity (Book Value) | 392.64M |
| Book Value Per Share | 6.14 |
| Working Capital | 244.99M |
Cash Flow
In the last 12 months, operating cash flow was -$166.99 million and capital expenditures -$6.56 million, giving a free cash flow of -$173.54 million.
| Operating Cash Flow | -166.99M |
| Capital Expenditures | -6.56M |
| Depreciation & Amortization | 33.75M |
| Net Borrowing | -44,000 |
| Free Cash Flow | -173.54M |
| FCF Per Share | -$2.58 |
Margins
Gross margin is 69.79%, with operating and profit margins of -205.72% and -191.99%.
| Gross Margin | 69.79% |
| Operating Margin | -205.72% |
| Pretax Margin | -212.72% |
| Profit Margin | -191.99% |
| EBITDA Margin | -179.91% |
| EBIT Margin | -205.72% |
| FCF Margin | n/a |
Dividends & Yields
DNA does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -11.06% |
| Shareholder Yield | -11.06% |
| Earnings Yield | -33.44% |
| FCF Yield | -20.83% |
Analyst Forecast
The average price target for DNA is $8.00, which is -35.33% lower than the current price. The consensus rating is "Sell".
| Price Target | $8.00 |
| Price Target Difference | -35.33% |
| Analyst Consensus | Sell |
| Analyst Count | 3 |
| Revenue Growth Forecast (3Y) | -18.36% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
| Graham Formula Value | n/a |
| Graham Formula Upside | n/a |
Stock Splits
The last stock split was on August 20, 2024. It was a reverse split with a ratio of 1:40.
| Last Split Date | Aug 20, 2024 |
| Split Type | Reverse |
| Split Ratio | 1:40 |
Scores
DNA has an Altman Z-Score of -9.28 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -9.28 |
| Piotroski F-Score | 3 |